Table 1.
Characteristics of included studies and pooled clinical outcomes.
| Characteristic | Summary data |
|---|---|
| Study information | |
| Studies (n) | 33 |
| Total Patients (n) | 2,095 |
| Study Design (%) | Single-arm (54.5)/Retrospective (36.4)/Prospective (9.1) |
| Patient characteristics | |
| Age Range | 4 months - 76 years |
| Disease Status | Relapsed/Refractory B-ALL (100%) |
| Treatment characteristics | |
| CAR-T Targets | CD19 (Dominant)/CD22/CD19+CD22 |
| Cell Dose | Median 5×106 cells/kg (0.5-67×106) |
| Lymphodepletion (%) | Flu/Cy (89)/Other (11) |
| Response rates | |
| Complete Remission | 64.9%-100% |
| MRD Negativity | 45%-100% |
| Toxicity incidence | |
| CRS (All Grades) | 55%-97.9% |
| CRS (≥Grade 3) | 10.2%-45% |
| ICANS (All Grades) | 19%-65% |
| ICANS (≥Grade 3) | 2.6%-45% |
| Survival outcomes | |
| 1-year OS | 54.8%-78.86% |
| 2-year EFS (MRD- vs MRD+) | 68% vs 23% |
| 4-year OS | 69.3% |